Partnering opportunity

New active principles for drugs useful in the treatment of inflammatory diseases, type 2 diabetes mellitus, hypercholesterolemia, dyslipidemias and atherosclerosis


A Spanish university has developed new drugs which reduce glucose and cholesterol levels with less toxicity compared to other similar compounds. This lower toxicity could imply the development of a more effective and tolerable treatment for these conditions. There are no natural derivative compounds with benzopyran structure on the market that regulates these metabolic alterations. Researchers are looking for license or technical cooperation agreements and/or financial agreements with investors.

Partner sought

- Type of partner sought: Enterprise, research centers or investors. - Specific area of activity of the partner: pharmaceutical activities, drug development, clinical trials. - Task to be performed: licensing the invention, testing the drug, carrying out clinical trials, production and marketing of the product. The Spanish university is looking for: • Pharma companies to reach license agreements • Pharma companies or research institutions to further co-development of the drug • Pharma companies or investors to carry out clinical trials


In the field of chemistry and pharmacology, different researchers have tried to develop treatments consisting of peroxisome proliferator-activated receptors agonists (PPARα and PPARγ), involved in the regulation of lipids, carbohydrates and inflammation, making them therapeutic targets for the treatment of type 2 diabetes, metabolic syndrome, obesity, hyperlipidemias, cardiovascular diseases (atherosclerosis) and neurodegenerative diseases. These compounds, in particular, the synthetic thiazolidinediones, have proved to be effective for treating some of these conditions, however, some of them failed due to their associated toxicity. Similarly, dual PPARα/PPARγ agonists such as saroglitazar are under surveillance. As a result, the treatment of the affected population is mainly carried out through a cocktail of different drugs such as statins, with their associated adverse effects, and hypoglycemic drugs. This invention is the solution to toxicity problems of the others PPAR α/γ agonists keeping treatment effectiveness. New compounds, Polycerasoidol and Polycerasoidin derivatives, have been developed to reduce glucose and cholesterol levels. The main application sector of these compounds would be the pharmaceutical sector, as they can be active principles of drugs for the treatment of type 2 diabetes mellitus, dyslipidemias, metabolic syndrome and associated complications such as cardiovascular, inflammatory diseases. It is a great market due to the percentage of the population affected by these metabolic disorders has increased mainly due to new lifestyle habits (sedentary lifestyle and increased consumption of processed foods). Researchers are seeking companies to reach license agreements. Technical cooperation with companies or research centers will be considered too, in order to make further progress in drug development. Finally, researchers are seeking investors interested in developing new drugs to carry out clinical trials through financial agreements.

Advantages and innovations

The most innovative aspect of this invention is that allows solving the toxicity problems of the others PPAR α/γ agonists keeping the treatment effectiveness. The main advantages provided by the invention are: - Lower toxicity of these compounds compared to other PPAR agonists. - Greater effectiveness against existing treatments such as cocktails of statins and hypoglycemic drugs

Development stage

Under development/lab tested

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted

Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company